Amgen Inc. (AMGN) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 23/100
- 10Y CAGR
- 5.4%
- Median YoY
- 4.8%
- YoY volatility
- σ 7.0pp· smooth
- Quarters ≥ 20%
- 3 of 40
- Negative quarters
- 10
- Valuation vs own 10Y history
- Latest historical P/S 5.7x · 10Y median 5.3x · 81st percentile · as of Oct 2, 2026
How this score is computed
- Quarters at or above 20%: 3 of 40 → 3 of 40 pts
- Steadiness (typical swing 7.0pp) → 20 of 25 pts
- Pace (median 4.8% YoY) → 0 of 20 pts
- Latest quarter (9.7% YoY) → 0 of 15 pts
- Score: 23 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 5.4% | 4.8% | 7.0pp | 3 of 40 | 10 |
| EPSEPS | 4.6% | 4% | 46.1pp | 8 of 40 | 16 |
| Op cash flowOperating cash flow | 0.9% | -0.8% | 44.1pp | 13 of 40 | 22 |
| EBITDAEBITDA | 4.1% | 5.2% | 20.6pp | 5 of 40 | 16 |
| FCFFree cash flow | -0.4% | -2.7% | 43.9pp | 12 of 40 | 20 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: AMGN on the compounders surface · All compounders, ranked